Get the Stockscreener App
7.1101
6.92%
-0.6199
Polyrizon Ltd stock is traded at $7.1101, with a volume of 21,339.
It is down -6.92% in the last 24 hours and up +88.58% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$7.73
Open:
$7.37
24h Volume:
21,339
Relative Volume:
0.01
Market Cap:
$7.41M
Revenue:
-
Net Income/Loss:
$-1.13M
P/E Ratio:
-0.1244
EPS:
-57.1626
Net Cash Flow:
$-2.63M
1W Performance:
-35.70%
1M Performance:
+88.58%
6M Performance:
+74.32%
1Y Performance:
-99.70%
1-Day Range:
$6.97
$7.37
1-Week Range:
$6.97
$11.26
52-Week Range:
$2.88
$4,200.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
7.111 | 8.05M | 0 | -1.13M | -2.63M | -57.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.44 | 116.79B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
791.51 | 81.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.11 | 53.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
855.29 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.58 | 37.48B | 447.02M | -1.18B | -906.14M | -6.1812 |
Polyrizon Ltd Stock (PLRZ) Latest News
What risks investors should watch in Polyrizon Ltd. stockWeekly Trade Report & Free Weekly Watchlist of Top Performers - Улправда
Aug Drivers: What risks investors should watch in Polyrizon Ltd. stock2025 Growth vs Value & Capital Protection Trade Alerts - Улправда
Polyrizon submits pre-request for designation to FDA for PL-16 viral blocker - marketscreener.com
Polyrizon Files FDA Pre-Request for Designation of PL-16 Intranasal Viral Blocker - TipRanks
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses - The Manila Times
Polyrizon Submits Pre-Request for Designation to FDA - One News Page
Is Polyrizon Ltd. stock undervalued vs historical averagesEarnings Growth Summary & Real-Time Market Sentiment Alerts - bolumsonucanavari.com
Winners Losers: Can Polyrizon Ltd stock attract ESG capital inflows2025 AllTime Highs & Breakout Confirmation Trade Signals - moha.gov.vn
Top Medical Stocks To Keep An Eye OnDecember 2nd - MarketBeat
Polyrizon unveils promising results for intranasal naloxone hydrogel - MSN
Resistance Check: Is Polyrizon Ltd stock a buy on dipsShort Setup & Safe Entry Point Identification - moha.gov.vn
Polyrizon completes FDA pre-submission meeting for PL-14 nasal spray - MSN
Polyrizon’s naloxone hydrogel shows positive permeation kinetics - TipRanks
Polyrizon’s intranasal naloxone hydrogel shows promising test results - Investing.com
Polyrizon Unveils Promising Results for Intranasal Naloxone Hydrogel - TipRanks
Polyrizon’s intranasal naloxone hydrogel shows promising test results By Investing.com - Investing.com Canada
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program - The Manila Times
[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC FilingForm 6-K - Stock Titan
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal ... - Enidnews.com
Polyrizon (Nasdaq: PLRZ) shows rapid permeation in intranasal naloxone hydrogel preclinical studies - Stock Titan
Polyrizon Ltd trading halted, news pending - MSN
Earnings Update: Is Polyrizon Ltd stock a buy on dipsJuly 2025 Action & Real-Time Stock Price Movement Reports - BỘ NỘI VỤ
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Polyrizon completes FDA pre-submission meeting for allergy blocker - Investing.com
Polyrizon Advances PL-14 Nasal Spray with FDA Meeting - TipRanks
Polyrizon completes FDA pre-submission meeting for allergy blocker By Investing.com - Investing.com India
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray - The Manila Times
Polyrizon completes FDA pre-submission meeting for PL-14 allergy blocker nasal spray - marketscreener.com
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray - GlobeNewswire Inc.
Top Biotech Stocks To ConsiderDecember 4th - MarketBeat
Small Cap Stocks To Keep An Eye OnDecember 4th - MarketBeat
Top Biotech Stocks To Consider – December 4th - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
This Former Penny Stock Just Doubled for the Second Time This Week. Should You Chase the Rally Here? - Barchart.com
Morning Market Movers: SMX, PRAX, PLRZ, RBRK See Big Swings - RTTNews
Polyrizon Ltd. Announces $4.97 Million Securities Offering - TipRanks
We Think Polyrizon (NASDAQ:PLRZ) Can Afford To Drive Business Growth - Yahoo Finance
Top Medical Stocks To Keep An Eye On – December 2nd - Defense World
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now - ts2.tech
Polyrizon Surges: A Game-Changer in Progress? - StocksToTrade
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025 - ts2.tech
Why Is Polyrizon Stock Skyrocketing Thursday?Polyrizon (NASDAQ:PLRZ) - Benzinga
Polyrizon (NASDAQ: PLRZ) Soars as Superior Mucoadhesion Naloxone Hydrogel Signals Stronger Real-World Opioid Overdose Reversal Potential - Barchart.com
Polyrizon (NASDAQ: PLRZ) Soars as Superior Mucoadhesion - openPR.com
Polyrizon Stock Skyrockets: What Sparked This Surge? - timothysykes.com
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection - The Manila Times
Morning Market Movers: PLRZ, PMI, CBIO, HY See Big Swings - RTTNews
Polyrizon (Nasdaq: PLRZ) scales PL-14 nasal spray output for planned 2026 clinical trials - Stock Titan
PLRZ Stock Price and Chart — NASDAQ:PLRZ - TradingView
Why Did Polyrizon Stock Soar Pre-Market Today? - Stocktwits
Polyrizon completes manufacturing upscaling milestone for nasal spray platform - MSN
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):